Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer
Z.-Y. Chen(Fudan University), Scott Kopetz(The University of Texas MD Anderson Cancer Center), Christopher H. Lieu(University of Colorado Denver), David S. Hong(The University of Texas MD Anderson Cancer Center), Kanwal Raghav(The University of Texas MD Anderson Cancer Center), John V. Heymach(The University of Texas MD Anderson Cancer Center), George J. Chang(The University of Texas MD Anderson Cancer Center), Hai T. Tran(The University of Texas MD Anderson Cancer Center), David G. Menter(The University of Texas MD Anderson Cancer Center), Paulo M. Hoff(Translational Research in Oncology), Michael J. Overman(The University of Texas MD Anderson Cancer Center), Jeffrey S. Morris(The University of Texas MD Anderson Cancer Center), Cathy Eng(Vanderbilt University)
Cited by 148
Related Papers
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k